Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

6533b831fe1ef96bd1298601

RESEARCH PRODUCT

Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

Vita Saripo Ilona Vanaga Dana Upite Emma Sokolova Ugis Kletnieks Gustavs Latkovskis Andrejs ĒRglis

subject

Male Ubiquinone Myopathy Pilot Projects 030204 cardiovascular system & hematology Gastroenterology Electrocardiography 0302 clinical medicine 030212 general & internal medicine Prospective Studies Prospective cohort study Pain Measurement Aged 80 and over Medicine(all)lcsh:R5-920 Muscle Weakness biology medicine.diagnostic_test Complete blood count Middle Aged Treatment Outcome Drug Therapy Combination Female medicine.symptom lcsh:Medicine (General)Glomerular Filtration Rate medicine.medical_specialty Statin medicine.drug_class Renal function Asymptomatic Polyprenols 03 medical and health sciences Double-Blind Method Internal medicine medicine Humans Myopathy Aged business.industry Terpenes Statins Myalgia medicine.disease Tracheophyta Automotive Engineering Physical therapy biology.protein Exercise Test Coenzyme Q10 Creatine kinase Hydroxymethylglutaryl-CoA Reductase Inhibitors business Statins; Myopathy; Polyprenols; Coenzyme Q10; Ubiquinone Biomarkers Kidney disease

description

Background and objective: Statin-induced myopathy (SIM) has been partially attributed to deficiency of dolichol and coenzyme Q10 (CoQ10). We aimed to test the safety and efficacy of plant polyprenols in combination with CoQ10 for alleviation of SIM. Materials and methods: In an open-label, one-center prospective pilot study patients with SIM received conifer-tree needle polyprenols (4 mg/day) and CoQ10 (100 mg/day) for 8 weeks. Symptoms and safety were evaluated according to symptom severity score (0–10), creatine kinase (CK) levels, exercise test, dynamometry, complete blood count, clinical biochemistry and electrocardiography. Results: Of the 14 patients, 11 completed the study per protocol. Two patients withdrew consent due to travels abroad, and it was discontinued for one patient with stage 3 chronic kidney disease due to asymptomatic elevations of liver enzymes at week 4. No safety parameters changed significantly in per protocol group. Non-significant increase of CK levels was observed (P = 0.231). Muscle pain (n = 10) and weakness (n = 7) scores improved significantly (P &lt

year	journal	country	edition	language
2016-05-30	Medicina

10.1016/j.medici.2016.05.002 http://dx.doi.org/10.1016/j.medici.2016.05.002